Obesity, a chronic disease established as a global epidemic by the World Health
Organization, is considered a risk factor for atrial fibrillation (AF), the most common …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …

Aims The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF)
patients treated with oral anticoagulation is unclear. Methods and results A total of 17 913 …

Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …

Although obesity is associated with the development and progression of atrial fibrillation
(AF), an obesity paradox may be present, illustrated by seemingly protective effects of …

Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

Background: Atrial fibrillation (AF) and obesity are common conditions globally; yet, there
remains suboptimal pharmacological management contributing to high rates of …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …